Just-Evotec Biologics expands COVID-19 contract with DOD

Just-Evotec Biologics announced a $28.6 million agreement with the Department of Defense to manufacture monoclonal antibodies for use against the COVID-19 virus. The antibody treatment will be manufactured in Just-Evotec’s facility in Redmond, Washington. The drug development has been in process since July 2020, originally starting in Just-Evotec’s Seattle pilot facility before transitioning to the larger space to accommodate for the production ramp-up.  

READ THE STORY at BioProcess International »